Home › Research › Long-term cohort studies
Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank
Jolanda Buonocore, Enrico Fratto, Fulvia Arcuri, Basilio Vescio, Camilla Calomino, Mariagrazia Talarico, Costanza Maria Cristiani, Aldo Quattrone et al.. Journal of Neurology, 2025-11-09
Topic: Brain proteins, microglia and lab models
Plain-language summary
The final sample included 1196 cases (505 PD, 26 APD, 476 AD, 189 ALS) and 44,107 control subjects. In Cox regression models, NfL was associated with higher risk of incident ALS (HR 1.69; 95% CI, 1.58-1.80, p < 0.001), APD (HR 1.51; 95% CI, 1.22-1.87, p < 0.001), AD (HR 1.31; 95% CI, 1.22-1.41, p < 0.001), and PD (HR 1.14; 95% CI, 1.05-1.23, p < 0.001). GFAP was independently associated with incident AD only (HR 1.72; 95% CI, 1.63-1.82, p < 0.001). Plasma NfL and GFAP showed distinct pre-diagnostic profiles. NfL was associated with incident diagnosis of several neurodegenerative diseases, while GFAP was specific to AD, reinforcing its role in dementia. These results may help optimize the identification of target populations at risk of neurodegenerative diseases for future neuroprotective treatments.
What this study adds
Evidence grade: Low
The record lists 1,196 participants. In this UK Biobank analysis, higher plasma NfL was linked to later diagnosis of several neurodegenerative diseases including Alzheimer's disease, while higher GFAP was linked specifically to Alzheimer's disease. Reported effect size: HR 1.69; HR 1.51; HR 1.31.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Buonocore, J., Fratto, E., Arcuri, F., Vescio, B., Calomino, C., Talarico, M., et al. (2025). Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank. Journal of Neurology. https://doi.org/10.1007/s00415-025-13498-y
Vancouver
Buonocore J, Fratto E, Arcuri F, Vescio B, Calomino C, Talarico M, et al. Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank. Journal of Neurology. 2025. doi:10.1007/s00415-025-13498-y. PMID: 41206819.
BibTeX
@article{buonocore2025-41206819,
author = {Buonocore, Jolanda and Fratto, Enrico and Arcuri, Fulvia and Vescio, Basilio and Calomino, Camilla and Talarico, Mariagrazia and Cristiani, Costanza Maria and Quattrone, Aldo and others},
title = {{Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank}},
journal = {Journal of Neurology},
year = {2025},
doi = {10.1007/s00415-025-13498-y},
pmid = {41206819},
url = {https://doi.org/10.1007/s00415-025-13498-y}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The final sample included 1196 cases (505 PD, 26 APD, 476 AD, 189 ALS) and 44,107 control subjects.
- In Cox regression models, NfL was associated with higher risk of incident ALS (HR 1.69; 95% CI, 1.58-1.80, p < 0.001), APD (HR 1.51; 95% CI, 1.22-1.87, p < 0.001), AD (HR 1.31; 95% CI, 1.22-1.41, p < 0.001), and PD (HR 1.14; 95% CI, 1.05-1.23, p < 0.001).
- GFAP was independently associated with incident AD only (HR 1.72; 95% CI, 1.63-1.82, p < 0.001).
- Plasma NfL and GFAP showed distinct pre-diagnostic profiles.
- NfL was associated with incident diagnosis of several neurodegenerative diseases, while GFAP was specific to AD, reinforcing its role in dementia.
Why it matters
In this UK Biobank analysis, higher plasma NfL was linked to later diagnosis of several neurodegenerative diseases including Alzheimer's disease, while higher GFAP was linked specifically to Alzheimer's disease. These blood markers may help identify people at risk of these diseases for future neuroprotective treatments, though the study does not test any treatment itself.
Study details
- Participants1,196
- Effect sizeHR 1.69; HR 1.51; HR 1.31
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Neurology) |
| Journal's citation record | 2 / 4 | Journal of Neurology: journal h-index 208 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,196 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 14 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 8.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Andrea Quattrone: h-index 33 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | National Research Council: institution h-index 840 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41206819) |
| Free to read | 2 / 2 | Free to read |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s00415-025-13498-y
- PubMed: 41206819
- Original source →
- Free full text: Journal of Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Long-term cohort studies from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.